Seeking Alpha

Leerink Swann calls the early success of Merck's (MRK +4.2%) odnacatib osteoporosis drug a...

Leerink Swann calls the early success of Merck's (MRK +4.2%) odnacatib osteoporosis drug a "positive upside surprise," and forecasts peak sales of $975M in 2020, and a total global sales potential of $3B+. Leerink Swann also maintains its Outperform rating on Merck's stock, while Citigroup ups its rating to "buy" from "neutral."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|